The study of Anavex2-73 in Patients With Rett Syndrome NCT03758924 being just a repeat of AD Phase 2a that is expolaratory turned out to be a shocker. A measure of behavioral "disruption" droped 30% from baseline which is 21% of the entire scale of 70 points. Even at just 6 patients the drop is statistically … Continue reading About Rett. $AVXL ANAVEX2-73 Blarcamesine

Alzheimer's trial as widow makers Dr Missling by choosing to have only 32 patients in Alzheimer's phase2a proved that he was very conservative with company's resources and not overly enthusiastic about ANAVEX2-73 prospects. Ask questions first, shoot later. The run up to $14 on hopes of "quick cure"="quick riches" was indeed a disappointment to shareholder … Continue reading CTAD 2020, PDD Phase2, way to partnership? $AVXL ANAVEX2-73 Blarcamesine

For number of years I have been speculating, fantasizing and making dumb-ass data analysis on ANAVEX2-73 Blarcamesine. My conviction that there, is there there was unwavering. We are coming into harvest season, though. Phase 2b/3 for Alzheimer's was posted since January 2nd 2019, so we are 22 months into the 48 weeks (11 months) dosing … Continue reading What about CTAD 2020? ANAVEX2-73 Blarcamesine $AVXL

Every investor and his aunty fret over the company not releasing yet the statistical data or "raw data" from PDD (Parkinson's Disease Dementia) phase 2 Clinical trial. From what the Dr. Missling said even the cohort with 30mg dose responded and that all the targets have been achieved with statistical significance. The last two words … Continue reading 15th of October 2020…comes another confirmation of blockbuster status of blarcamesine Anavex 2-73. $AVXL